{"id":33122,"date":"2025-05-09T18:45:04","date_gmt":"2025-05-09T10:45:04","guid":{"rendered":"https:\/\/flcube.com\/?p=33122"},"modified":"2025-05-09T18:45:05","modified_gmt":"2025-05-09T10:45:05","slug":"jjs-tremfya-approved-for-ulcerative-colitis-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33122","title":{"rendered":"J&J’s Tremfya Approved for Ulcerative Colitis in China"},"content":{"rendered":"\n

US giant Johnson & Johnson (J&J, NYSE: JNJ<\/a>) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Tremfya (guselkumab) intravenous infusion (IV) and Tremfya (guselkumab) injection. The drug is now approved for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients who have had an insufficient response, lost response, or are intolerant to traditional treatments or biologics.<\/p>\n\n\n\n

Tremfya’s Previous Approvals<\/strong>
Tremfya, a monoclonal antibody against interleukin-23, was previously approved in China for the treatment of moderate to severe plaque psoriasis and moderate to severe active Crohn’s disease (CD).<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The approval is based on results from the Phase IIb\/III QUASAR study. The study demonstrated that patients treated with guselkumab experienced significant symptom improvement as early as Week 1 compared to placebo, with the therapeutic effect progressively strengthening over 12 weeks. Notably, 50% of patients in the 200mg Q4W dose group and 45% in the 100mg Q8W dose group achieved the primary endpoint of clinical remission at week 44, both significantly higher than the placebo group at 19%. The endoscopic remission rate of the guselkumab group was also significantly higher than that of the placebo group (p<0.001).-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval…<\/p>\n","protected":false},"author":1,"featured_media":33123,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[150,149,858,15],"class_list":["post-33122","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-jj","tag-johnson-johnson","tag-nyse-jnj","tag-product-approvals"],"yoast_head":"\nJ&J's Tremfya Approved for Ulcerative Colitis in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Tremfya (guselkumab) intravenous infusion (IV) and Tremfya (guselkumab) injection. The drug is now approved for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients who have had an insufficient response, lost response, or are intolerant to traditional treatments or biologics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33122\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&J's Tremfya Approved for Ulcerative Colitis in China\" \/>\n<meta property=\"og:description\" content=\"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Tremfya (guselkumab) intravenous infusion (IV) and Tremfya (guselkumab) injection. The drug is now approved for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients who have had an insufficient response, lost response, or are intolerant to traditional treatments or biologics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33122\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-09T10:45:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-09T10:45:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0916.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&J’s Tremfya Approved for Ulcerative Colitis in China\",\"datePublished\":\"2025-05-09T10:45:04+00:00\",\"dateModified\":\"2025-05-09T10:45:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0916.webp\",\"keywords\":[\"J&J\",\"Johnson & Johnson\",\"NYSE: JNJ\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33122#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33122\",\"name\":\"J&J's Tremfya Approved for Ulcerative Colitis in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0916.webp\",\"datePublished\":\"2025-05-09T10:45:04+00:00\",\"dateModified\":\"2025-05-09T10:45:05+00:00\",\"description\":\"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Tremfya (guselkumab) intravenous infusion (IV) and Tremfya (guselkumab) injection. The drug is now approved for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients who have had an insufficient response, lost response, or are intolerant to traditional treatments or biologics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33122\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0916.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0916.webp\",\"width\":1080,\"height\":608,\"caption\":\"J&J's Tremfya Approved for Ulcerative Colitis in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33122#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&J’s Tremfya Approved for Ulcerative Colitis in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&J's Tremfya Approved for Ulcerative Colitis in China - Insight, China's Pharmaceutical Industry","description":"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Tremfya (guselkumab) intravenous infusion (IV) and Tremfya (guselkumab) injection. The drug is now approved for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients who have had an insufficient response, lost response, or are intolerant to traditional treatments or biologics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33122","og_locale":"en_US","og_type":"article","og_title":"J&J's Tremfya Approved for Ulcerative Colitis in China","og_description":"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Tremfya (guselkumab) intravenous infusion (IV) and Tremfya (guselkumab) injection. The drug is now approved for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients who have had an insufficient response, lost response, or are intolerant to traditional treatments or biologics.","og_url":"https:\/\/flcube.com\/?p=33122","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-09T10:45:04+00:00","article_modified_time":"2025-05-09T10:45:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0916.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33122#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33122"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&J’s Tremfya Approved for Ulcerative Colitis in China","datePublished":"2025-05-09T10:45:04+00:00","dateModified":"2025-05-09T10:45:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33122"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33122#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0916.webp","keywords":["J&J","Johnson & Johnson","NYSE: JNJ","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33122#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33122","url":"https:\/\/flcube.com\/?p=33122","name":"J&J's Tremfya Approved for Ulcerative Colitis in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33122#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33122#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0916.webp","datePublished":"2025-05-09T10:45:04+00:00","dateModified":"2025-05-09T10:45:05+00:00","description":"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its Tremfya (guselkumab) intravenous infusion (IV) and Tremfya (guselkumab) injection. The drug is now approved for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients who have had an insufficient response, lost response, or are intolerant to traditional treatments or biologics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33122#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33122"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33122#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0916.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0916.webp","width":1080,"height":608,"caption":"J&J's Tremfya Approved for Ulcerative Colitis in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33122#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&J’s Tremfya Approved for Ulcerative Colitis in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0916.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33122"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33122\/revisions"}],"predecessor-version":[{"id":33124,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33122\/revisions\/33124"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33123"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}